Ellen Hukkelhoven Net Worth

Ellen Hukkelhoven biography

Ellen Hukkelhoven Ph.D. serves as Independent Director of the Company. Dr. Hukkelhoven has served as a member of our Board of Directors since October 2017. Since 2018, Dr. Hukkelhoven has served as a Managing Director at Perceptive Advisors, a leading healthcare investment firm, prior to which she served as a Senior Analyst since 2013. Prior to joining Perceptive Advisors in 2013, Dr. Hukkelhoven received an B.A. in molecular biology and finance from Princeton University and a Ph.D. in cancer biology from Memorial Sloan Kettering Cancer Center.

What is the salary of Ellen Hukkelhoven?

As the Independent Director of MeiraGTx plc, the total compensation of Ellen Hukkelhoven at MeiraGTx plc is $385,750. There are 13 executives at MeiraGTx plc getting paid more, with Alexandria Forbes having the highest compensation of $8,480,260.

How old is Ellen Hukkelhoven?

Ellen Hukkelhoven is 33, she's been the Independent Director of MeiraGTx plc since 2017. There are 17 older and no younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.

What's Ellen Hukkelhoven's mailing address?

Ellen's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.

Insiders trading at MeiraGTx plc

Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus és Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.

What does MeiraGTx plc do?

meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.

MeiraGTx plc executives and stock owners

MeiraGTx plc executives and other stock owners filed with the SEC include:

• Alexandria Forbes,
  President, Chief Executive Officer, Director
• Richard Giroux,
  Chief Financial Officer, Chief Operating Officer
• Dr. Alexandria Forbes,
  CEO, Pres & Director
• Martin Indyk,
  Independent Director
• Richard Brian Giroux B.A.,
  COO & CFO
• Stuart Naylor,
  Chief Development Officer
• Dr. Stuart Naylor Ph.D.,
  Chief Devel. Officer
• Nicole Seligman,
  Independent Director
• Keith Harris,
  Independent Chairman of the Board
• Neil Mendoza,
  Independent Director
• Joel Marcus,
  Independent Director
• Arnold Levine,
  Independent Director
• Thomas Shenk,
  Independent Director
• Ellen Hukkelhoven,
  Independent Director
• Elizabeth Broder,
  Investor Relations
• Dr. Robert K. Zeldin M.D.,
  Chief Medical Officer
• Dr. Alastair Leighton,
  Sr. VP of Manufacturing & Supply Chain
• Tim Randall,
  Sr. VP of Risk & Internal Controls
• Joel P. Brooks,
  Sr. VP of Fin.
• Christine Elise Sheehy,
  Sr. VP of Global Integration
• Dr. Michel Michaelides M.D.,
  Head of Clinical Ophthalmology
• Robert J. Wollin J.D.,
  Gen. Counsel & Sec.
• & Johnson Innovation Jjdc...,
  10% owner
• Advisors Llcperceptive Life...,
  
• Katherine Breedis,
  Chief Financial Officer
• Life Sciences Master Fund L...,
  
• Bruce Gottlieb,
  General Counsel
• Advisors Llcedelman Joseph ...,
  
• Debra Yu,
  
• Robert K Zeldin,
  CHIEF MEDICAL OFFICER
• Robert J Wollin,
  GENERAL COUNSEL AND SECRETARY